Rein Therapeutics
RNTX
17 hedge funds and large institutions have $957K invested in Rein Therapeutics in 2019 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 11 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
6.72% less ownership
Funds ownership: 12.72% → 6% (-6.7%)
23% less funds holding
Funds holding: 22 → 17 (-5)
45% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 11
60% less capital invested
Capital invested by funds: $2.37M → $957K (-$1.41M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair & Company
Chicago,
Illinois
|
+$148K |
| 2 |
Renaissance Technologies
New York
|
+$74.4K |
| 3 |
PCS
Personal CFO Solutions
Chester,
New Jersey
|
+$18.3K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$18.2K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$1.65K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$1.23M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$368K |
| 3 |
PVI
Pura Vida Investments
New York
|
-$91K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$67K |
| 5 |
VF
Virtu Financial
New York
|
-$45K |
RNTX Hedge Fund Activity: Q4 2019 in Review
17 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q4 2019, worth a combined $957K — down 60% from $2.37M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of RNTX and 6 opened new positions — a net loss of 5 holders — while 2 trimmed existing stakes and 3 added.
The largest buyer was William Blair & Company, adding an estimated $148K. The largest seller was Jennison Associates, exiting entirely with an estimated $1.23M sold.
- 17 institutional investors held Rein Therapeutics (RNTX) as of Q4 2019, down from 22 in Q3 2019.
- Funds reported $957K of Rein Therapeutics stock for Q4 2019, down 60% quarter-over-quarter.
- 6 funds opened new Rein Therapeutics positions in Q4 2019 and 11 closed out, a net change of -5 holders.
- The largest Rein Therapeutics buyer in Q4 2019 was William Blair & Company, an estimated $148K added.
- The largest Rein Therapeutics seller in Q4 2019 was Jennison Associates, an estimated $1.23M sold.
Based on aggregated 13F filings for Q4 2019.